CG Oncology's PIVOT-006 Hits Primary Endpoint: 68% Recurrence Risk Cut, BLA Set for March 2027
CGON has more than doubled off its 52-week low of $37.01 on elevated volume (3.3× avg).
Summary
CG Oncology's Phase 3 PIVOT-006 trial met its primary endpoint, with cretostimogene cutting recurrence risk 68% versus surveillance (HR 0.32, p<0.0001) and no Grade 3+ treatment-related adverse events. The company now expects to complete its first BLA in March 2027, broadened to include high-grade papillary-only BCG-unresponsive disease, with a second BLA in intermediate-risk and high-grade Ta NMIBC in Q2 2027.
Key Events · Product Development and Regulatory · CGON
-
PIVOT-006 Meets Primary Endpoint
Cretostimogene reduced the risk of recurrence by 68% versus surveillance, a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001), with median follow-up of 17 months as of the October 26, 2026 cutoff.
-
Clean Safety Profile
No Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations, consistent with prior studies.
-
First BLA Broadened, March 2027
Based on FDA feedback, the BCG-unresponsive NMIBC BLA now also covers high-grade papillary-only disease (without CIS), with completion anticipated in March 2027.
-
Second BLA Set for Q2 2027
PIVOT-006 data will support a second BLA submission in intermediate-risk and high-grade Ta NMIBC anticipated in the second quarter of 2027; all BLA-enabling manufacturing activities for both filings are complete.
Analysis · CGON · Life Sciences
This is the pivotal readout the entire CG Oncology story rested on. In intermediate-risk and high-grade Ta NMIBC—a population of roughly 50,000 U.S. patients with no FDA-approved adjuvant option—cretostimogene cut the risk of recurrence by 68% versus surveillance (hazard ratio 0.32, p<0.0001). The safety profile held up as well, with no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations; for a drug meant to be given like BCG in urology clinics, that matters as much as efficacy. The filing also resets the regulatory calendar. The first BLA in BCG-unresponsive NMIBC is now broadened to include high-grade papillary-only disease, with completion expected in March 2027, and a second BLA in intermediate-risk and high-grade Ta disease is planned for Q2 2027. That pushes the first approval decision into 2027 rather than sooner, so the near-term question shifts from 'does the drug work' to 'does the FDA agree with the data and how broad is the label.'
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGON was trading at $99.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $37.01 to $80.97. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.